Noxopharm Limited (NOX.AX)

0.1000 +0.0020 (+2.04%) At close: 04:10PM AEST

Noxopharm Limited

60 Linksley Avenue
Glenhaven, NSW 2156
Australia

https://www.noxopharm.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Gisela Mautner	CEO, Executive MD & Director	491.56k	N/A	N/A
Mr. Shawn Van Boheemen FCPA, J.P.	Chief Financial Officer	N/A	N/A	N/A
Ms. Jeanette Bell Ph.D.	Chief Operating Officer	N/A	N/A	N/A
Dr. John Wilkinson B.Sc., Ph.D.	Chief Scientific Officer of Oncology	N/A	N/A	N/A
Dr. Olivier Laczka B.S., M.Sc., Ph.D.	Chief Scientific Officer of Inflammation	N/A	N/A	N/A
Mr. David James Franks BEc, C.A., F Fin, J.P.	Company Secretary	N/A	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Corporate governance

Noxopharm Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.